3-carboethoxy-4-methyl-2-chloropyrrole | 158692-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-carboethoxy-4-methyl-2-chloropyrrole
• 英文别名: Ethyl 2-chloro-5-methyl-1H-pyrrole-3-carboxylate
• CAS: 158692-50-3
• 化学式: C₈H₁₀ClNO₂
• 分子量: 187.626
• InChiKey: UUJGQBITLMZKNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-carboethoxy-4-methyl-2-chloropyrrole 在 palladium 10% on activated carbon 甲酸铵 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 5-甲基-1H-吡咯-3-羧酸乙酯
  参考文献：
  名称：

  EP2154139

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氰基-4-氧代戊酸乙酯 在 盐酸 作用下， 以 异丙醇 为溶剂， 以96%的产率得到3-carboethoxy-4-methyl-2-chloropyrrole
  参考文献：
  名称：

  有效合成2-氯-3-羰基乙氧基或2-氯-3-氰基4,5-二取代和5-取代的吡咯

  摘要：

  取代的2-氰基-4-氧代链烷酸乙酯或2-氰基-4-氧代烷腈与2-丙醇中的HCl气体或2-丙醇中的浓HCl的反应为二腈提供了有效的合成取代的2-易得的原料和试剂中的氯吡咯。

  DOI：

  10.1016/0040-4039(94)88056-5
• 作为试剂：
  描述：

  3-carboethoxy-4-methyl-2-chloropyrrole 、 二碳酸二叔丁酯 在 4-二甲氨基吡啶 、 3-carboethoxy-4-methyl-2-chloropyrrole 二氯甲烷 、 水 、 magnesium sulfate 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以to give an oil (20 g)的产率得到1-(1,1-dimethylethyl) 3-ethyl 2-chloro-5-methyl-1H-pyrrole-1,3-dicarboxylate
  参考文献：
  名称：

  CHEMICAL COMPOUNDS

  摘要：

  本发明涉及6-(4-嘧啶基)-1H-吲唑衍生物。具体而言，本发明涉及公式（I）中R1-R4所定义的化合物。本发明的化合物是PDK1的抑制剂，可用于治疗免疫和代谢性疾病和障碍，这些疾病和障碍以恒定激活的ACG激酶为特征，例如乳腺、结肠和肺癌等。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制PDK1活性和治疗相关障碍的方法。

  公开号：

  US20110275611A1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059658A1

  公开（公告）日：2010-05-27

  The invention is directed to 6-(4-pyιϊmidinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及6-(4-吡咯嗪基)-1 H-吲唑衍生物。具体而言，该发明涉及符合式(I)的化合物，其中R1-R4在此处被定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于恒定激活的ACG激酶所特征化的免疫和代谢性疾病和紊乱，如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• Bicyclic Heterocyclic Compound
  申请人：Nakai Hisao

  公开号：US20100184771A1

  公开（公告）日：2010-07-22

  A compound represented by the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof: wherein X 1 represents N and X 2 represents C, or X 1 represents C and X 2 represents N; Y 1 represents CR 4 or N; Y 2 represents CH or N; wherein both Y 1 and Y 2 do not represent N at the same time; R 1 represents (1) C3-10 branched alkyl which may be substituted or (2) —(CH 2 ) m —NR 5 R 6 ; R 2 , R 3 , and R 4 each independently represent H, C1-4 alkyl, a halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or the like; R 5 and R 6 each independently represent C1-6 alkyl which may be substituted, or R 5 represents H, and R 6 represents C3-6 branched alkyl which may be substituted; and Ar represents an aromatic ring which may be substituted, is useful as a pharmacologically active ingredient having a CRF antagonistic activity in preventing and/or treating neuropsychiatric diseases, diseases of peripheral organs or the like.

  化合物的化学式为(I)，其盐，N-氧化物，溶剂合物或前药：其中X1代表N，X2代表C，或者X1代表C，X2代表N；Y1代表CR4或N；Y2代表CH或N；其中Y1和Y2不能同时代表N；R1代表(1) C3-10支链烷基，可以被取代或(2) -(CH2)m-NR5R6; R2、R3和R4各自独立地代表H、C1-4烷基、卤代C1-4烷基、C2-4烯基、C2-4炔基或类似物；R5和R6各自独立地代表C1-6烷基，可以被取代，或者R5代表H，R6代表C3-6支链烷基，可以被取代；Ar代表一个芳香环，可以被取代，其在预防和/或治疗神经精神疾病、外周器官疾病或类似疾病方面具有CRF拮抗活性的药理活性成分。
• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Saito Tetsuji

  公开号：US20100137318A1

  公开（公告）日：2010-06-03

  A compound of a formula (I): wherein R 1 represents a C3-10 branched alkyl group which may be substituted; R 2 represents a hydrogen atom or a C1-4 alkyl group which may be substituted; R 3 represents a C1-4 alkyl group which may be substituted or a halogen atom; R 4 represents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.

  化合物的化学式（I）：其中R1代表一个C3-10支链烷基，可以被取代; R2代表氢原子或C1-4烷基，可以被取代; R3代表C1-4烷基，可以被取代或卤素原子; R4代表C1-4烷基，可以被取代; 环1表示具有平面性且可能具有取代基团的环状基团，其盐，其N-氧化物或其溶剂化物，或其前药，可用作具有CRF拮抗活性的药物成分，用于预防和/或治疗神经精神疾病，外周器官疾病等。
• Bicyclic heterocyclic compound
  申请人：Saito Tetsuji

  公开号：US08420810B2

  公开（公告）日：2013-04-16

  A compound of a formula (I): wherein R1 represents a C3-10 branched alkyl group which may be substituted; R2 represents a hydrogen atom or a C1-4 alkyl group which may be substituted; R3 represents a C1-4 alkyl group which may be substituted or a halogen atom; R4 represents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.

  化合物的式子（I）：其中R1代表一个C3-10支链烷基，可以被取代; R2代表氢原子或C1-4烷基，可以被取代; R3代表C1-4烷基，可以被取代或卤素原子; R4代表C1-4烷基，可以被取代; 环1代表一个具有平面性且可能具有取代基团的环状基团，其盐，N-氧化物或溶剂化物，或其前药，可用作具有CRF拮抗活性的药物成分，用于预防和/或治疗神经精神疾病，外周器官疾病等。
• Chemical compounds
  申请人：Axten Jeffrey Michael

  公开号：US08697685B2

  公开（公告）日：2014-04-15

  The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及6-(4-嘧啶基)-1H-吲唑衍生物。具体而言，本发明涉及公式(I)中R1-R4所定义的化合物。本发明的化合物是PDK1的抑制剂，可用于治疗免疫和代谢性疾病和障碍，这些疾病和障碍以恒定激活的ACG激酶为特征，例如乳腺癌、结肠癌和肺癌等癌症。因此，本发明进一步涉及包括本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包括本发明化合物的药物组合物来抑制PDK1活性和治疗与之相关的疾病的方法。